Showing 511-520 of 7932 results for "".
Increasing Patient Compliance with the Right Vehicles
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/increasing-patient-compliance-with-the-right-vehicles/18877/Peter Lio, MD and Elaine Siegfried, MD talk about their vehicles of choice to enhance patient adherence to treatment, especially when treating scalp psoriasis. They also discuss how packaging innovations have led to vehicle innovations.Make a Profound Impact
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/make-a-profound-impact/18886/Macrene Alexiades, MD, Ph.D, shares her experience with the Profound system, a micro-needling RF device, with real-time temperature feedback mechanism that improves mandibular and submandibular contouring. The device works by stimulating collagen, elastin and hyaluronic acid resulting in a youthfulDerms Fight MOC; Cipher Buys Innocutis
https://practicaldermatology.com/topics/practice-management/dermwiretv-derms-fight-moc-cipher-buys-innocutis/18930/The AAD asks the American Board of Dermatology for changes to Maintenance of Certification (MOC) requirements; Jeanine Downie, MD and Heidi Waldorf, MD discuss problems with current and proposed requirements. Galderma presents data to support new investigational adapalene 0.3%/benzoyl peroxide 2.5%The Importance of Being Thorough
https://practicaldermatology.com/topics/practice-management/the-importance-of-being-thorough/19027/Kristina Goldenberg, MD talks about lessons learned in residency, particularly the importance being thorough with patients.Derm Insider: Ethics and Industry: How to Manage Relationships with Pharma
https://practicaldermatology.com/topics/practice-management/derm-insider-ethics-and-industry-how-to-manage-relationships-with-pharma/19029/In this edition, host Neal Bhatia, MD and guests Tom Prunty and James Q. Del Rosso, DO tackle the ethics of industry relationships. They discuss the nuances and challenges of physicians fostering appropriate relationships with pharmaceutical manufacturers amid an increasingly stringent regulatory laPROLITE III, IPL System by Quantel Derma
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/prolite-iii-ipl-system-by-quantel-derma/19374/PROLITE III by Quantel Derma - The Right Choice for the Right Pulse. The powerful intense pulsed light system (IPL) - high-speed treatments for photo rejuvenation and permanent hair removal. An effective contact cooling is integrated in the handpieces. A variable pulse formation makes PROLITE III exBehavioral Interview Considerations
https://practicaldermatology.com/conferences/noah-worcester/behavioral-interview-considerations/57077/Robert Brodell, MD, discusses his presentation, “Helping Students 'Ace' their Behavioral Interview for Medical School or Residency,” from the Noah Worcester Dermatological Society’s 2026 Annual Meeting.Addressing Itch in Prurigo Nodularis Clinical Trials
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37170/Raja Sivamani, MD, MS, AP, an integrative dermatologist and Adjunct Associate Professor of Clinical Dermatology at the University of California, Davis, addresses how future prurigo nodularis trials could better address the heterogeneity in disease burden and patient-reported outcomes.Innovation in Androgenetic Alopecia
https://practicaldermatology.com/series/c-suite-chats/innovation-in-androgenetic-alopecia/54265/Diana Harbort, President of Cosmo Pharmaceuticals' Dermatology Division, discusses the need for new innovations in androgenetic alopecia and the promise of clascoterone for treating the condition.Dermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-ruxolitinib-cream-15-effective-for-ad-improvement-stapokibart-shows-promise/49101/This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research valida